m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05003
 [1]
Non-coding RNA VPS9D1-AS1 ELAVL1  lncRNA       miRNA   circRNA Direct Enhancement m6A modification CDK4 CDK4 ELAVL1 : m6A sites
m6A Modification:
m6A Regulator ELAV-like protein 1 (ELAVL1) READER
 Regulator Info 
m6A Target Cyclin-dependent kinase 4 (CDK4)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator VPS9D1 antisense RNA 1 (VPS9D1-AS1) LncRNA View Details
Regulated Target ELAV-like protein 1 (HuR/ELAVL1) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary VPS9D1-AS1 silencing suppressed HCC tumor growth in vivo. Mechanistically, VPS9D1-AS1 was able to bind to ELAVL1 and thereby influence the stability and expression of the Cyclin-dependent kinase 4 (CDK4) mRNA, thus impacting HCC cell proliferation. The VPS9D1-AS1/HuR/CDK4 signaling axis regulates HCC tumor cell oncogenic activity, highlighting this pathway as a promising therapeutic target.
Responsed Disease Liver cancer ICD-11: 2C12
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Cyclin-dependent kinase 4 (CDK4) 62 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Palbociclib Approved [2]
Synonyms
571190-30-2; PD0332991; PD-0332991; Ibrance; PD 0332991; UNII-G9ZF61LE7G; Palbociclib(PD0332991); 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one; G9ZF61LE7G; PD 332991; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE; LQQ; PD 332991, PD 0332991, PD0332991; 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one; 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one; HMR-2934
    Click to Show/Hide
MOA Modulator
Activity IC50 = 9 nM
External Link
CID: 5330286
TTD: D00UZR
DrugBank: DB09073
 Compound Name Ribociclib Succinate Approved [3]
Synonyms
1374639-75-4; LEE011 succinate; LEE011 (succinate); UNII-BG7HLX2919; LEE011-BBA; Ribociclib succinate [USAN]; BG7HLX2919; Kisqali (TN); Ribociclib succinate (USAN); LEE-011 succinate; SCHEMBL2684999; EX-A1586; HY-15777B; 1374639-75-4 (succinate); AKOS030526460; CS-2277; ACN-040739
    Click to Show/Hide
MOA Modulator
External Link
CID: 57334219
TTD: D01HVT
 Compound Name LY2835219 Approved [4]
Synonyms
Abemaciclib; 1231929-97-7; Verzenio; LY-2835219; UNII-60UAB198HK; LY2835219 (free base);
    Click to Show/Hide
MOA Modulator
Activity IC50 = 2 nM
External Link
CID: 46220502
TTD: D05SBO
DrugBank: DB12001
 Compound Name Trilaciclib Approved [5]
Synonyms
G1T28; 1374743-00-6; Trilaciclib [USAN]; G1T28(Trilaciclib); GTPL9626; CHEMBL3894860; SCHEMBL10082028; BDBM253928; US9464092, T; HY-101467; CS-0021431; 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro(cyclohexane-1,9'-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one; Spiro(cyclohexane-1,9'(6'H)-pyrazino(1',2':1,5)pyrrolo(2,3-d)pyrimidin)-6'-one, 7',8'-dihydro-2'-((5-(4-methyl-1-piperazinyl)-2-pyridinyl)amino)-; 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyra
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 68029831
TTD: D0AP9E
DrugBank: DB15442
 Compound Name Apremilast Approved [6]
Synonyms
Apremilast (USAN); CC-10004; N-[2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethyl]-1,3-dioxo-isoindol-4-yl]acetamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11561674
TTD: D07ESC
DrugBank: DB05676
 Compound Name LEE011 Phase 3 [7]
Synonyms
Ribociclib; 1211441-98-3; LEE-011; Kisqali; Ribociclib(LEE011); UNII-TK8ERE8P56; LEE 011; 7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; TK8ERE8P56; Ribociclib (LEE011); AK174906; 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide; 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo [2,3-d]pyrimidine-6-carboxylic acid dimethylamide; Ribociclib [USAN:INN]; LEE011A; Tube013
    Click to Show/Hide
MOA Modulator
Activity IC50 = 2 nM
External Link
CID: 44631912
TTD: D08MXP
DrugBank: DB11730
 Compound Name P-276 Phase 2 [8]
Synonyms
CDK4 inhibitor (cancer), Nicholas Piramal; P-664-02; CDK4 inhibitor (iv, cancer), Piramal Life Sciences; CDK4 inhibitor(iv, cancer), NPIL Research & Development
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 23643976
TTD: D0W8IY
 Compound Name G1T38 Phase 2 [9]
Synonyms
YPJRHEKCFKOVRT-UHFFFAOYSA-N; SCHEMBL16036885; CHEMBL3904602; BDBM253941; US9464092, GG; 1628256-23-4
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 86269224
TTD: D0WU1O
 Compound Name Ro 31-7453 Phase 2 [10]
Synonyms
Bisindolylmaleimide deriv. 44; MKC-1; Ro-31-7453; 3-(1-methylindol-3-yl)-4-(1-methyl-6-nitroindol-3-yl)pyrrole-2,5-dione
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5327686
TTD: D01UMT
DrugBank: DB05608
 Compound Name P276-00 Phase 2 [11]
Synonyms
CHEMBL2312181; SCHEMBL1180418
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 23643975
TTD: D05IRT
 Compound Name GLR2007 Phase 1/2 [12]
MOA Inhibitor
External Link
TTD: D4IS0G
 Compound Name FCN-437 Phase 1/2 [13]
MOA Inhibitor
External Link
TTD: D8ZV2Q
 Compound Name NUV-422 Phase 1/2 [14]
MOA Inhibitor
External Link
TTD: D70HZT
 Compound Name P1446A-05 Phase 1 [11]
MOA Inhibitor
Activity IC50 < 100 nM
External Link
CID: 67409219
TTD: D0DX4J
DrugBank: DB15157
 Compound Name PF-07220060 Phase 1 [15]
MOA Inhibitor
External Link
TTD: DZJ3D5
 Compound Name G1T28-1 Phase 1 [4]
MOA Modulator
External Link
TTD: D01XZG
 Compound Name AG-024322 Phase 1 [11]
Synonyms
AG-24322; N-[[5-[(3E)-3-(4,6-difluorobenzimidazol-2-ylidene)-1,2-dihydroindazol-5-yl]-4-methylpyridin-3-yl]methyl]ethanamine
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135413565
TTD: D0IX4B
DrugBank: DB13035
 Compound Name PHA-793887 Phase 1 [8]
Synonyms
Cyclin-dependent kinase inhibitor (cancer), Nerviano
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 46191454
TTD: D0P1CV
DrugBank: DB12686
 Compound Name RGT-419B Phase 1 [16]
MOA Inhibitor
External Link
TTD: DYH94Z
 Compound Name FN-1501 Phase 1 [17]
Synonyms
1429515-59-2; CHEMBL4077071; UNII-6MC966B505; TQR1001; BDBM50270304; NSC781143; 6MC966B505; NSC-781143; HY-111361; CS-0039834; 4((7HPyrrolo[2,3d]pyrimidin-4-yl)amino)N(4-((4-methylpiperazin-1-yl)methyl)phenyl)1Hpyrazole-3-carboxamide; 4-((7H-Pyrrolo (2,3-d)pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide; 4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-5-carboxamide; 4a?(7Ha'Pyrrolo[2,3a'd]pyrimidin-4-yl)amino)a'Na?4-((4-methylpiperazin-1-yl)methyl)phenyl)a?Ha'pyrazole-3-carboxamide; N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 72195175
TTD: DKCU40
 Compound Name RGB-286638 Phase 1 [8]
Synonyms
GPC-286199; RGB-286199; RGB-344064; Non-selective CDK inhibitors, Agennix; Non-selective CDK inhibitors, GPC Biotech; Non-selective cyclin dependent kinase inhibitors, Agennix; Non-selective cyclin dependent kinase inhibitors, GPC Biotech
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11285001
TTD: D03DKV
 Compound Name Imidazo pyridine derivative 3 Patented [18]
Synonyms
PMID26161698-Compound-22
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 46937330
TTD: D0WT7D
 Compound Name Palbociclib/ribociclib analog 1 Patented [18]
Synonyms
PMID26161698-Compound-4
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 89798202
TTD: D03HED
 Compound Name Pyrrolo[2,3-d]pyrimidine derivative 10 Patented [18]
Synonyms
PMID26161698-Compound-2
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 53378895
TTD: D04AKA
 Compound Name PMID26161698-Compound-17 Patented [18]
MOA Inhibitor
External Link
CID: 739323
TTD: D0FQ6V
 Compound Name Pyrrolo[2,3-d]pyrimidine derivative 9 Patented [18]
Synonyms
PMID26161698-Compound-1
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 1 nM
External Link
CID: 44818950
TTD: D08KKC
 Compound Name PMID25726713-Compound-49 Patented [19]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D07TVO
 Compound Name PMID25726713-Compound-51 Patented [19]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0KH7Q
 Compound Name Indole-based analog 13 Patented [18]
Synonyms
PMID26161698-Compound-20
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 73293
TTD: D0LX6X
 Compound Name Isoquinoline 1,3-dione derivative 1 Patented [18]
Synonyms
PMID26161698-Compound-49
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
TTD: D0W4MN
 Compound Name PMID25726713-Compound-48 Patented [19]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0WJ3W
 Compound Name PMID25726713-Compound-47 Patented [19]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0X5VI
 Compound Name PMID25726713-Compound-50 Patented [19]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0Y8JF
 Compound Name PMID25991433-Compound-A1 Patented [20]
MOA Inhibitor
Activity IC50 = 910 nM
External Link
TTD: D0H4HD
 Compound Name Oxazolyl methylthiothiazole derivative 1 Patented [18]
Synonyms
PMID26161698-Compound-52
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 100 nM
External Link
CID: 25195503
TTD: D0M5DX
 Compound Name BAY 10-00394 Discontinued in Phase 2 [8]
Synonyms
roniciclib; BAY 1000394; KB-145902; 1223498-69-8; Tube010; SCHEMBL875845; GTPL7874
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 45380979
TTD: D0NV9O
 Compound Name R547 Discontinued in Phase 1 [11]
Synonyms
LIA; R-547; [4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6918852
TTD: D04FHB
DrugBank: DB08094
 Compound Name ZK 304709 Discontinued in Phase 1 [11]
Synonyms
1010440-84-2; ZK CDK; UNII-87GI98VT0I; SCHEMBL955299; 87GI98VT0I; DTXSID20143701
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 59733314
TTD: D00VBT
 Compound Name INOC-005 Preclinical [8]
Synonyms
Capridine beta (prostate cancer), Prostagenics
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07ZJC
 Compound Name CYC-103 Terminated [8]
Synonyms
Cyclin groove inhibitors, Cyclacel; CYC-103 (Pimetics series); CYC-103 cyclin groove inhibitors, Cyclacel; CYC-103 program, Cyclacel
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0Y6HA
 Compound Name PD-0183812 Terminated [21]
Synonyms
PETCVZZPKYJZAU-UHFFFAOYSA-N; PD183812; AC1NS8PJ; CHEMBL139653; SCHEMBL5268115; BDBM6280; PD 0183812; N8 Pyrido[2,3-d]pyrimidin-7-one deriv 72; 8-{bicyclo[221]heptan-2-yl}-2-({4-[4-(3-hydroxypropyl)piperidin-1-yl]phenyl}amino)-7H,8H-pyrido[2,3-d]pyrimidin-7-one; 8-(3-bicyclo[221]heptanyl)-2-[4-[4-(3-hydroxypropyl)piperidin-1-yl]anilino]pyrido[2,3-d]pyrimidin-7-one; PD0183813
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 20 nM
External Link
CID: 5330258
TTD: D0Z0KD
 Compound Name N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide Investigative [22]
Synonyms
CHEMBL521733; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 787236
TTD: D03VDM
 Compound Name 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea Investigative [23]
Synonyms
Diarylurea deriv. 14a; AC1NS9HT; BDBM6656; CHEMBL143759; ZINC13471116; AKOS027814075; 3-1H-indazol-6-yl-1-pyridin-2-ylurea; 1-(1H-indazol-6-yl)-3-pyridin-2-ylurea; N-(1H-Indazol-6-yl)-N -pyridin-2-ylurea
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5330597
TTD: D0G4JS
 Compound Name 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea Investigative [23]
Synonyms
Diarylurea deriv. 14; AC1NS9HN; CHEMBL140624; BDBM6654; ZINC13471112; 1-(7-Hydroxy-1-naphthyl)-3-(2-pyridyl)urea; N-(7-Hydroxy-1-naphthyl)-N -pyridin-2-ylurea; 1-(7-hydroxynaphthalen-1-yl)-3-pyridin-2-ylurea
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5330595
TTD: D0M8CO
 Compound Name 1-Pyridin-2-yl-3-quinolin-5-yl-urea Investigative [23]
Synonyms
Diarylurea deriv. 14b; AC1NS9HW; BDBM6657; CHEMBL143704; ZINC13471117; 1-pyridin-2-yl-3-quinolin-5-ylurea; 3-pyridin-2-yl-1-quinolin-5-ylurea; 1-(5-Quinolyl)-3-(2-pyridyl)urea; N-Pyridin-2-yl-N -quinolin-5-ylurea
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5330598
TTD: D0T2VG
 Compound Name 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea Investigative [23]
Synonyms
Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5330596
TTD: D0X1NW
 Compound Name Cdk4 inhibitor III Investigative [24]
Synonyms
Ryuvidine; 265312-55-8; CHEMBL290904; 2-Methyl-5-[(4-methylphenyl)amino]benzothiazole-4,7-dione; 5-(N-(4-Methylphenyl)amino)-2-methyl-4,7-dioxobenzothiazole; 2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione; AC1Q6BBC; AC1LA59T; 2-Methyl-5-p-tolylamino-benzothiazole-4,7-dione; SCHEMBL2169284; GTPL5952; CTK4F8075; CHEBI:92119; AOB6479; MolPort-023-276-509; HMS3269F11; HMS3229E08; ZINC5930916; BDBM50086655; 2-METHYL-5-[(4-METHYLPHENYL)AMINO]-4,7-BENZOTHIAZOLEDIONE; AKOS024457195; CCG-206830
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 6000 nM
External Link
CID: 481747
TTD: D07HPE
 Compound Name Fascaplysin Investigative [21]
Synonyms
Pyrido[1,2-a:3,4-b']diindol-5-ium,12,13-dihydro-13-oxo-, chloride; GNF-PF-1458; ACMC-20bu3v; AC1L2JLY; AC1Q6JA3; SCHEMBL1728912; CHEMBL602937; GTPL5969; BDBM59087; CTK4A8872; CHEBI:93765; ZINC1616841; pyrido[1,2-a:3,4-b']diindol-5-ium, 12,13-dihydro-13-oxo-; HSCI1_000331; NCGC00346951-01; CJ-26101; BRD-K13287209-003-03-2; BRD-K13287209-311-02-1; BRD-K13287209-311-01-3; BRD-K13287209-003-02-4; BRD-K13287209-003-01-6
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 350 nM
External Link
CID: 73292
TTD: D09OAH
 Compound Name Ro-0505124 Investigative [25]
Synonyms
RO0505124
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9911652
TTD: D09RYV
 Compound Name NSC-625987 Investigative [26]
Synonyms
NSC 625987
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3004085
TTD: D0VD8B
 Compound Name 10-hydroxy-18-methoxybetaenone Investigative [27]
Synonyms
CHEMBL498247; BDBM50269144
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10644450
TTD: D0W6CE
 Compound Name PYRAZOLOPYRIDAZINE 1 Investigative [28]
Synonyms
551920-54-8; GW810576X; n-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinamine; pyrazolo[1,5-b]pyridazine deriv. 19; AC1O6ZIQ; CHEMBL187081; BDBM8128; SCHEMBL4489357; CTK1F7320; DTXSID60424889; HMS3305F24; HMS3303K24; ZINC13582569; NCGC00242229-01; DA-42106; FT-0707969; AB01092291-01; 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-yl-; N-(3-methoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 60 nM
External Link
CID: 6539361
TTD: D02DLC
 Compound Name K00024 Investigative [29]
Synonyms
indolocarbazole deriv. 4(d)
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5330797
TTD: D0D5HQ
 Compound Name PYRAZOLOPYRIDAZINE 2 Investigative [28]
Synonyms
pyrazolo[1,5-b]pyridazine deriv. 25; AC1O6ZJ2; BDBM8134; CHEMBL186054; N-(3,4-dimethoxyphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 190 nM
External Link
CID: 6539367
TTD: D0O0VP
 Compound Name PMID18986805C9b Investigative [30]
Synonyms
GTPL8160; BDBM50246396; ZINC38224644
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 50 nM
External Link
CID: 11675054
TTD: D0P6JS
 Compound Name NU-6102 Investigative [31]
Synonyms
nu6102; 444722-95-6; NU 6102; O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE; Cdk1/2 Inhibitor II, NU6102; 6-Cyclohexylmethoxy-2-(4&amp; -sulfamoylanilino)purine; 4-{[6-(cyclohexylmethoxy)-9H-purin-2-yl]amino}benzenesulfonamide; 4SP; 1h1s; 4-[[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino]benzenesulfonamide; 4-{[6-(cyclohexylmethoxy)-7h-purin-2-yl]amino}benzenesulfonamide; 4-[[6-(cyclohexylmethoxy)-9h-purin-2-yl]amino]benzenesulfonamide; 4eor; 4eok; 2iw9; 2c6o; 2iw8; AC1L1IGA; SCHEMBL2170816; CHEMBL319467
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1600 nM
External Link
CID: 4566
TTD: D0Y5RO
DrugBank: DB07126
 Compound Name NU6140 Investigative [32]
Synonyms
Cdk2 Inhibitor IV, NU6140; 444723-13-1; NU 6140; CHEMBL1802728; 4-(6-Cyclohexylmethoxy-9H-purin-2-ylamino)-N,N-diethylbenzamide; 4-{[6-(cyclohexylmethoxy)-7H-purin-2-yl]amino}-N,N-diethylbenzamide; Cdk2 inhibitor IV; SCHEMBL2169233; GTPL5949; CTK8E7940; DTXSID30436732; MolPort-023-276-742; MolPort-044-561-419; HMS3229E18; IN1369; ZINC22309248; BDBM50347924; AKOS024457537; CCG-206836; NCGC00370819-01; NU6140, &gt; RT-011957; 4-(6-cyclohexylmethoxy-9hpurin-2-ylamino)-N,N-diethyl-benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10202471
TTD: D04WFN
 Compound Name 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione Investigative [33]
Synonyms
CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 15422868
TTD: D06AOY
 Compound Name 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione Investigative [33]
Synonyms
1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10946795
TTD: D00NYT
 Compound Name 3,4-diphenyl-1H-pyrrole-2,5-dione Investigative [33]
Synonyms
2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 2752461
TTD: D0C3WY
 Compound Name 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione Investigative [33]
Synonyms
CHEMBL372076; SCHEMBL3822337
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11572699
TTD: D0EK0G
 Compound Name 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol Investigative [34]
MOA Inhibitor
External Link
CID: 9859248
TTD: D0A5RM
2C12: Liver cancer 49 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name 90Y-loaded resin microspheres Approved [35]
External Link
TTD: DGWE36
 Compound Name Thymalfasin Phase 2 [36]
Synonyms
Zadaxin; 62304-98-7; Thymosin alpha1; Thymosin alpha 1; Thymosin alpha1 (ox); Thymosin alpha1 (human); Thymalfasin [USAN:INN]; UNII-W0B22ISQ1C; Thymosin-alpha-1; 69440-99-9; Thymosin alpha1 (cattle); C129H215N33O55; W0B22ISQ1C; Zadaxin (TN); Thymalfasin alfa 1
    Click to Show/Hide
External Link
CID: 16130571
TTD: D0I5KX
 Compound Name Ferumoxides Approved [37]
Synonyms
AMI-25; 119683-68-0; Feridex; Feridex IV; Superparamagnetic iron oxide; UNII-G6N3J05W84; Ferumoxides [USAN:USP:BAN]; CCRIS 6722; HSDB 8072; AC1O5DID; G6N3J05W84; iron(2+); iron(3+); Iron oxide crystal is inverse spinel (X-ray data); Fe(II) and Fe(III) are present (Mossbauer Spectroscopy; Physical form is a colloidal particle of nonstoichiometric
    Click to Show/Hide
External Link
CID: 6432052
TTD: D08QAC
DrugBank: DB06215
 Compound Name DTI-015 Approved [38]
Synonyms
Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics
    Click to Show/Hide
External Link
CID: 2578
TTD: D01OXI
DrugBank: DB00262
 Compound Name Nofazinlimab Phase 3 [39]
Synonyms
CS1003; EQ176
    Click to Show/Hide
External Link
TTD: DX9GT7
 Compound Name PV-10 Phase 3 [9]
Synonyms
632-69-9; Rose bengal sodium; Rose bengal disodium salt; R105 sodium; Rose-bengal (131 I) natrium; Food Red No 105, sodium salt; EINECS 211-183-3; Food Red Color No 105, sodium salt; Sel disodique de rose bengale iodee (131 I); Rose bengale (131 I) sodique [INN-French]; Rosa bengala sodica (131 I) [INN-Spanish]; Roseum bengalense (131 I) natricum [INN-Latin]; 2,4,5,7-Tetraido(m,p,o',m')tetrachlorofluorescein, disodium salt; Fluorescein, 4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-, disodium salt; Disodium
    Click to Show/Hide
External Link
CID: 69438
TTD: D0L2VT
 Compound Name Brivanib Phase 3 [40]
Synonyms
649735-46-6; BMS-540215; Brivanib (BMS-540215); BMS 540215; UNII-DDU33B674I; Brivanib [USAN]; BMS540215; DDU33B674I; CHEMBL377300; (2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]propanol; Brivanib (USAN); (2R)-1-[4-[(4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY]-5-METHYL-PYRROLO[2,1-F][1,2,4]TRIAZIN-6-YL]OXYPROPAN-2-OL; (2R)-1-({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-ol
    Click to Show/Hide
External Link
CID: 11234052
TTD: D0HS5V
DrugBank: DB11958
 Compound Name JX-594 Phase 3 [41]
Synonyms
Pexastimogene devacirepvec
    Click to Show/Hide
External Link
TTD: D0HB0V
 Compound Name ABH001 Phase 3 [42]
External Link
TTD: D05LPP
 Compound Name MTC-DOX Phase 2/3 [43]
Synonyms
MTC-doxorubicin
    Click to Show/Hide
External Link
TTD: D0W9AI
 Compound Name KD018 Phase 2 [44]
External Link
TTD: D0NB9T
 Compound Name Doxorubicin-eluting beads Phase 2 [45]
Synonyms
DC Bead (TN)
    Click to Show/Hide
External Link
TTD: D0M5CD
 Compound Name 32-P BioSilicon Phase 2 [46]
Synonyms
BrachySil
    Click to Show/Hide
External Link
TTD: D0M1YS
 Compound Name Cixutumumab Phase 2 [47]
Synonyms
LY3012217
    Click to Show/Hide
External Link
TTD: D0E5DP
 Compound Name [131I]-Metuximab Phase 2 [48]
External Link
TTD: D0E5BW
 Compound Name Darinaparsin Phase 2 [49]
Synonyms
ZIO-101
    Click to Show/Hide
External Link
CID: 11683005
TTD: D03ZME
DrugBank: DB06179
 Compound Name Tigatuzumab Phase 2 [50]
External Link
TTD: D03LTO
 Compound Name CMC-001 Phase 2 [51]
Synonyms
Manganese-based MRI contrast agent (liver tumor imaging), CMC Contrast
    Click to Show/Hide
External Link
TTD: D00WMJ
 Compound Name OBP-301 Phase 1/2 [52]
External Link
TTD: D0D8ZK
 Compound Name MBO7133 Phase 1/2 [53]
External Link
TTD: D0C3MW
 Compound Name INCB62079 Phase 1/2 [9]
External Link
TTD: D0BE8H
 Compound Name NV-1020 Phase 1/2 [54]
External Link
TTD: D0B6EA
 Compound Name DCVax-Liver Phase 1/2 [55]
Synonyms
Dendritic cell-based immunotherapy (liver cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D00ESH
 Compound Name SRF388 Phase 1 [56]
External Link
TTD: DLY89F
 Compound Name ET140202 Phase 1 [57]
External Link
TTD: D4K2OF
 Compound Name ADP-A2AFP Phase 1 [58]
External Link
TTD: D31ORV
 Compound Name SM04755 Phase 1 [59]
External Link
TTD: D0P5XM
 Compound Name Anti-CEA CAR-T therapy Phase 1 [9]
External Link
TTD: D0OP1L
 Compound Name PI-166 Phase 1 [60]
External Link
TTD: D0J2YR
 Compound Name CRS-100 Phase 1 [61]
External Link
TTD: D0B4DL
 Compound Name Autologous ET1402L1-CART cells Phase 1 [62]
External Link
TTD: D09TGO
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [63]
External Link
TTD: D09HRH
 Compound Name MRX34 Phase 1 [64]
External Link
TTD: D08SJY
 Compound Name ALN-VSP Phase 1 [65]
External Link
TTD: D08JMI
 Compound Name EPCAM-targeted CAR-T cells Clinical trial [66]
External Link
TTD: D0T8DD
 Compound Name ADI Discontinued in Phase 3 [67]
Synonyms
Arginine deiminase
    Click to Show/Hide
External Link
CID: 46906074
TTD: D0O4EV
 Compound Name GN-1140 Discontinued in Phase 2 [68]
External Link
TTD: D0V4CL
 Compound Name OGT-719 Discontinued in Phase 2 [69]
Synonyms
OGS-719
    Click to Show/Hide
External Link
CID: 9838997
TTD: D0C2CH
 Compound Name AFP-Scan Discontinued in Phase 2 [70]
External Link
TTD: D08CCC
 Compound Name SR1078 Preclinical [71]
Synonyms
1246525-60-9; SR 1078; SR-1078; N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-4-(trifluoromethyl)benzamide; CHEMBL3094387; N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-4-(trifluoromethyl)benzamide; N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-4-(trifluoromethyl)benzamide; SCHEMBL4880524; C17H10F9NO2; DTXSID30591895; BCP09203; EX-A2215; 4063AH; BDBM50444350; s5775; ZINC98052696; AKOS024458390; CS-1045; NCGC00379222-02; AK547149; AS-55921; HY-14422; W-5797; SR-03000001078; SR-03000001078-1; SR-03000001078-2
    Click to Show/Hide
External Link
CID: 17980288
TTD: D9D6QN
 Compound Name Occlusin Preclinical [72]
Synonyms
Occlusin 50 Injection; Occlusin 500 injection
    Click to Show/Hide
External Link
TTD: D00INM
 Compound Name HRC-201 Terminated [73]
Synonyms
Hemoglobin-imaging conjugate (HepSelect), Hemosol
    Click to Show/Hide
External Link
TTD: D09ZCH
 Compound Name 1,2,3,4,5,6-hexabromocyclohexane Investigative [74]
Synonyms
1837-91-8; Benzene hexabromide; Cyclohexane, 1,2,3,4,5,6-hexabromo-; Hexabromocyclohexane; JAK2 Inhibitor II; ACMC-1BQJT; SCHEMBL459442; trans-alpha-Benzene hexabromide; CHEMBL444236; DTXSID4052687; CHEBI:93940; NSC7908; HMS3268H22; HMS3413C10; HMS3677C10; NSC-7908; ZINC1586309; ANW-23174; MFCD00059127; s5902; Cyclohexane,2,3,4,5,6-hexabromo-; AKOS015836040; 1,2,3,4,5,6-Hexabromo-cyclohexane; 1,2,3,4,5,6-Hexabromocyclohexane #; NCGC00092358-01; NCGC00092358-02; 1,2,3,4,5,6-hexakis(bromanyl)cyclohexane; A4510; FT-0633875; JAK2 Inhibitor II - CAS 1837-91-8; 1,2,3,4,5,6-Hexabromocyclohexane;NSC7908; A812818; 1,2,3,4,5,6-Hexabrom-cyclohexan (I(2)-Form); J-011778; 1,2,3,4,5,6-Hexabromocyclohexane, >=98% (HPLC); BRD-K06817181-001-01-5; Q27165694
    Click to Show/Hide
External Link
CID: 74603
TTD: DLW69V
 Compound Name STP-322 Investigative [75]
Synonyms
Multi-targeted siRNA therapeutic cocktail (nanoparticle, liver tumor), Sirnaomics
    Click to Show/Hide
External Link
TTD: D0R8KF
 Compound Name AMB-8LK Investigative [75]
Synonyms
Cancer therapy (monoclonal antibody), MAT Biopharma; Y90 anti-ferritin monoclonal antibody (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (cancer), MAT Biopharma; Yttrium-90 anti-ferritin mAb (Hodgkin's disease/pancreatic/liver cancer), MAT Biopharma; 90Y-AMB8LK mAb (cancer), MAT Biopharma; 90Y-AMB8LK monoclonal antibody (cancer), MAT Biopharma; 90Y-labelled anti-ferritin monoclonal antibody (cancer), MAT Biopharma
    Click to Show/Hide
External Link
TTD: D0P2MD
 Compound Name MiR-34a mimics Investigative [75]
Synonyms
MiR-34a mimics (liver cancer)
    Click to Show/Hide
External Link
TTD: D0M9TD
 Compound Name P53 fusion protein Investigative [75]
Synonyms
P53 fusion protein (pancreatic/liver cancer)
    Click to Show/Hide
External Link
TTD: D06WLG
 Compound Name OP-05 Investigative [75]
Synonyms
OP-05 program (prodrug, liver tumor); OP-05 program (prodrug, liver tumor), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D02OIP
 Compound Name GR-DD1 Investigative [75]
Synonyms
Cytotoxin (hepatic metastasis), ERYtech
    Click to Show/Hide
External Link
TTD: D00QFV
References
Ref 1 The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis. DNA Cell Biol. 2021 Oct;40(10):1278-1289. doi: 10.1089/dna.2021.0235. Epub 2021 Sep 24.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 4 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 6 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
Ref 7 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. doi: 10.1158/1078-0432.CCR-13-1675. Epub 2013 Sep 17.
Ref 8 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. Epub 2010 Dec 27.
Ref 9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 10 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 11 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. doi: 10.1038/nrd2907.
Ref 12 Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals.
Ref 13 Clinical pipeline report, company report or official report of Fochon Pharmaceuticals.
Ref 14 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
Ref 15 ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health.
Ref 16 Clinical pipeline report, company report or official report of Regor Therapeutics
Ref 17 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. doi: 10.1021/acs.jmedchem.7b01261. Epub 2018 Feb 12.
Ref 18 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014). Expert Opin Ther Pat. 2015;25(9):953-70. doi: 10.1517/13543776.2015.1045414. Epub 2015 Jul 13.
Ref 19 Hedgehog inhibitors: a patent review (2013 - present). Expert Opin Ther Pat. 2015 May;25(5):549-65. doi: 10.1517/13543776.2015.1019864. Epub 2015 Mar 1.
Ref 20 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Epub 2015 May 19.
Ref 21 Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. doi: 10.1016/s0165-6147(02)02071-0.
Ref 22 Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39. doi: 10.1016/j.bmc.2008.07.002. Epub 2008 Jul 8.
Ref 23 Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. doi: 10.1021/jm0103256.
Ref 24 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4. doi: 10.1016/s0960-894x(00)00014-7.
Ref 25 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976).
Ref 26 The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86.
Ref 27 Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45. doi: 10.1021/np9905259.
Ref 28 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. J Med Chem. 2004 Sep 9;47(19):4716-30. doi: 10.1021/jm040063i.
Ref 29 Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. doi: 10.1021/jm0256169.
Ref 30 Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. doi: 10.1016/j.bmcl.2008.10.075. Epub 2008 Oct 22.
Ref 31 Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7. doi: 10.1021/jm060216x.
Ref 32 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. doi: 10.1158/1535-7163.MCT-05-0022.
Ref 33 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 34 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740.
Ref 35 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
Ref 36 ClinicalTrials.gov (NCT01031966) A Pilot Study to Evaluate ZADAXIN's (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine. U.S. National Institutes of Health.
Ref 37 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 38 Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62.
Ref 39 ClinicalTrials.gov (NCT04194775) A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC). U.S.National Institutes of Health.
Ref 40 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5671).
Ref 41 ClinicalTrials.gov (NCT02017678) Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin. U.S. National Institutes of Health.
Ref 42 ClinicalTrials.gov (NCT01749306) A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing. U.S. National Institutes ofHealth.
Ref 43 ClinicalTrials.gov (NCT00034333) Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer. U.S. National Institutes of Health.
Ref 44 ClinicalTrials.gov (NCT00730158) A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026037)
Ref 46 PRODUCTS: BrachySil. Psivida corp
Ref 47 ClinicalTrials.gov (NCT01232452) A Study in Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 48 ClinicalTrials.gov (NCT00819650) A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection. U.S. National Institutes of Health.
Ref 49 ClinicalTrials.gov (NCT00421213) Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers. U.S. National Institutes of Health.
Ref 50 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021589)
Ref 52 ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.
Ref 53 Clinical pipeline report, company report or official report of Metabasis Therapeutics (2006).
Ref 54 ClinicalTrials.gov (NCT00149396) Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to Treat Colorectal Cancer Metastatic to Liver. U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT01882946) Safety and Efficacy Study of DCVax-Direct in Solid Tumors. U.S. National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT04374877) Study of SRF388 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT03965546) Clinical Study of ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Advanced Liver Cancer. U.S.National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT03132792) A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFP????T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types. U.S.National Institutes of Health.
Ref 59 ClinicalTrials.gov (NCT02191761) Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. U.S. National Institutes of Health.
Ref 60 Clinical pipeline report, company report or official report of Progen.
Ref 61 ClinicalTrials.gov (NCT00327652) Study of Safety and Tolerability of Intravenous CRS-100 in Adults With Carcinoma and Liver Metastases. U.S. National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma
Ref 63 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 64 ClinicalTrials.gov (NCT01829971) A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection. U.S. National Institutes of Health.
Ref 65 Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
Ref 66 ClinicalTrials.gov (NCT02729493) Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer
Ref 67 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003116)
Ref 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015394)
Ref 69 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009854)
Ref 70 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008092)
Ref 71 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 72 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018427)
Ref 73 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020214)
Ref 74 Leptin increases the expression of the iron regulatory hormone hepcidin in HuH7 human hepatoma cells. J Nutr. 2007 Nov;137(11):2366-70.
Ref 75 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.